Another investigation revealed that IL-17A increased expression of PD-L1 on CRC cells and that inhibition of IL-17A improved the efficacy of anti-PD-1 therapy in a murine MSS CRC model [204,205]. This evidence concerns the gene IL17A and colorectal carcinoma.